Compare VIR & ATEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIR | ATEC |
|---|---|---|
| Founded | 2016 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2019 | 2006 |
| Metric | VIR | ATEC |
|---|---|---|
| Price | $11.79 | $10.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 14 |
| Target Price | ★ $20.78 | $15.79 |
| AVG Volume (30 Days) | 1.7M | ★ 2.3M |
| Earning Date | 11-04-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 17.49 | 15.04 |
| EPS | ★ N/A | N/A |
| Revenue | $68,556,000.00 | ★ $101,739,000.00 |
| Revenue This Year | $257.66 | $15.43 |
| Revenue Next Year | N/A | $15.24 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.82 | $6.82 |
| 52 Week High | $11.94 | $23.29 |
| Indicator | VIR | ATEC |
|---|---|---|
| Relative Strength Index (RSI) | 62.59 | 59.60 |
| Support Level | $8.43 | $8.86 |
| Resistance Level | $11.77 | $11.03 |
| Average True Range (ATR) | 0.57 | 0.39 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 92.24 | 72.46 |
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
Alphatec Holdings Inc is a medical technology company focused on the designing, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma. The company's spine approach technologies include Posterior Cervical Fusion, Anterior Cervical Discectomy and Fusion, Lateral Interbody Fusion, and Posterior Lumbar Interbody Fusion among others. Its procedural offerings are designed to address the underlying causes of spinal pathology by advancing the three fundamental objectives of spine surgery: (1) decompression of neural elements, (2) stabilization of spinal segments, and (3) restoration and maintenance of proper spinal alignment.